drug_type
RELEVANT_DRUG
intervention_type
cell therapy
drug_description
Autologous/allogeneic CD3+CD56+ NKT-like effector cells expanded ex vivo; provide MHC-unrestricted cytotoxicity via NKG2D recognition of stress ligands (e.g., MICA/B, ULBPs) and killing through perforin/granzyme and Fas/FasL; used to target B-ALL blasts and support persistence/function of prior CAR-T cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer T-Cells
drug_category
CULTURED CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Ex vivo–expanded CD3+CD56+ cytokine-induced killer (CIK) cells exert MHC-unrestricted cytotoxicity via NKG2D recognition of stress ligands (e.g., MICA/B, ULBPs) on leukemia cells, mediating killing through perforin/granzyme release and Fas/FasL interactions; they also produce cytokines and can support the persistence and function of previously infused CAR-T cells.
drug_name
Cytokine-induced killer (CIK) cells
nct_id_drug_ref
NCT06389305